🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Susana Banerjee

Royal Marsden NHS Foundation Trust

ORCID: 0000-0002-8840-7934

Also affiliated with Institute of Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study”.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Nature Cancer(2021)10.1038/s43018-021-00274-w
N/A
6.8DataRank · unranked
185 citations

Scott T.C. Shepherd, Lewis Au, Katalin A. Wilkinson, Mary Wu, Fiona Byrne +91 more

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Journal of Clinical Oncology(2020)10.1200/jco.20.01164
N/A
4.6DataRank · unranked
153 citations

Rachel N. Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero +25 more

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0103
N/A
1.8DataRank · unranked
76 citations

Joshy George, Chen Wang, Timothy Budden, Tuan Zea Tan, Derek S. Chiu +134 more

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0621
N/A
0.949DataRank · unranked
22 citations

Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza +25 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045
N/A
0.920DataRank · unranked
18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005919
N/A
0.812DataRank · unranked
25 citations

Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley +16 more

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Journal of Clinical Oncology(2025)10.1200/jco-25-00112
N/A
0.722DataRank · unranked
36 citations

Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew R. Clamp +20 more

Prognostic gene expression signature for high-grade serous ovarian cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.05.019
N/A
0.718DataRank · unranked
119 citations

S. Chen, Blake Gilks, C. Wang, S.C.Y. Leung, V. Chow +387 more

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-3042
N/A
0DataRank · unranked
2 citations

Austin Miller, Heather A. Lankes, Kwong‐Kwok Wong, William H. Rodgers, David Millan +20 more

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

Journal of Clinical Oncology(2020)10.1200/jco.20.01924
N/A
0DataRank · unranked
315 citations

Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman +11 more

Recent advancements of antiangiogenic combination therapies in ovarian cancer

Cancer Treatment Reviews(2021)10.1016/j.ctrv.2021.102224
N/A
0DataRank · unranked
80 citations

Susana Banerjee, Jungmin Lee, Daniel An

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240
N/A
0DataRank · unranked
15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260
N/A
0DataRank · unranked
6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Two decades of advances in clinical oncology — lessons learned and future directions

Nature Reviews Clinical Oncology(2024)10.1038/s41571-024-00945-4
N/A
0DataRank · unranked
23 citations

Christopher M. Booth, Éduardo Bruera, Markus W. Büchler, Alexander Drilon, Terry J. Fry +14 more

Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer

Cancer Cell(2025)10.1016/j.ccell.2025.07.005
N/A
0DataRank · unranked
24 citations

Fabrizio Benedetti, Aspram Minasyan, Mathieu Desbuisson, Paula Cunnea, Alizée J Grimm +37 more